The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential…
Intrepid Recovery Center's Founder, John Nash Pakel, Champions the Next Phase in Addiction Treatment with the Introduction of PHP -…
BayMark's Study Demonstrates the Path to More Successful Opioid Use Disorder TreatmentLEWISVILLE, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- BayMark,…
BRENTWOOD, TN / ACCESSWIRE / November 28, 2023 / Odyssey Behavioral Healthcare, a leading provider of mental health, eating disorder,…
The pre- clinical trial conducted using the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule TEL AVIV,…
Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite…
CHATHAM, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products…
Cedar Recovery Expands Leadership with Dr. Stuart Ross as Medical Director for Cookeville Office, Bringing Extensive Addiction Medicine Expertise and…
BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…
AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use DisorderToronto,…